Lysteda Pediatric Research Equity Act (PREA) Pharmacokinetic Study in Adolescent Females With Heavy Menstrual Bleeding

NCT ID: NCT01190150

Last Updated: 2012-07-16

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-08-31

Study Completion Date

2011-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase 4, randomized, 2-way crossover, pharmacokinetic study of Lysteda (tranexamic acid) tablets administered as single doses of 0.65 g and 1.3 g in fasting adolescent female subjects ages 12-16 years with heavy menstrual bleeding.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Menorrhagia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Cyclic Heavy Menstrual Bleed Menorraghia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

0.65 g / 1.3 g tranexamic acid

Participants received a single dose of 0.65 g tranexamic acid on Day 1 and a single dose of 1.3 g tranexamic acid on Day 8.

Group Type EXPERIMENTAL

tranexamic acid

Intervention Type DRUG

Either one or two modified-immediate release tranexamic acid tablets (0.65 g each) taken orally, administered with 240 mL of water, as a single dose, at approximately 8 AM.

1.3 g / 0.65 g tranexamic acid

Participants received a single dose of 1.3 g tranexamic acid on Day 1 and a single dose of 0.65 g tranexamic acid on Day 8.

Group Type EXPERIMENTAL

tranexamic acid

Intervention Type DRUG

Either one or two modified-immediate release tranexamic acid tablets (0.65 g each) taken orally, administered with 240 mL of water, as a single dose, at approximately 8 AM.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

tranexamic acid

Either one or two modified-immediate release tranexamic acid tablets (0.65 g each) taken orally, administered with 240 mL of water, as a single dose, at approximately 8 AM.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Lysteda modified-immediate release tranexamic acid

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Generally healthy non-smoking (for at least 3 months) adolescent females 12-16 years of age with a history of at least 1 year of cyclic heavy menstrual bleeding (HMB)
* Subjects must report regularly occurring menstrual periods ≤10 days in duration, with 21-45 days from the start of one period to the start of the next menstrual period
* Diagnosis of HMB based on the medical judgment of the Principal Investigator and will include the following criteria:

1. Laboratory (including a bleeding disorders work-up) and Physical Findings;
2. Limitations in Activities of Daily Living (ADL);
3. Soiling, Staining and Clotting;
4. Sanitary product usage and extent of MBL using a patient reported pictorial blood assessment chart (PBAC).
* Subjects should either be sexually inactive (abstinent) or be using one of the following acceptable birth control methods and agree to continue its use throughout the study:

* copper intrauterine device (IUD) in place for at least 3 months;
* barrier methods (condom, diaphragm) with spermicide for at least 1 month prior to the first dose and throughout the study.
* Negative pregnancy test results
* Subject's legally authorized representative (e.g., parent, guardian) must voluntarily sign a parental permission/informed consent form (ICF), and the subject must sign an assent, before the conduct of any study procedure

Exclusion Criteria

* Breast-feeding, or a history of abortion in the last 6 months
* Known bleeding or coagulation disorders based on medical history and/or laboratory results
* Known systemic hematologic diseases (e.g., all types of sickle-cell disease, thalassemia of all types, multiple myeloma, hemolytic anemia)
* Clinical evidence of any significant chronic illness, including cardiovascular, renal, neurologic, hepatic, endocrine, gastric, central nervous system disease, any psychiatric illness which could affect the efficacy or safety of study medication
* Subjects treated with systemic steroids in the last 1 month or hormonal treatment in the last 3 months
* A history or presence of any drug abuse or alcohol abuse within the last 1 year
* History of subarachnoid hemorrhage.
* Active thromboembolic disease; history of thrombosis or thromboembolism, including retinal vein or artery occlusion; an intrinsic risk of thrombosis or thromboembolism
* Use of vaginal hormone products (rings, creams, and gels) within 4 weeks prior to screening. Use of oral estrogen-, progestin-, or selective estrogen receptor within 8 weeks prior to screening. Use of Lupron (3-month depot injection), estrogen pellet, or long-acting progestin injectables within 6 months prior to screening
* Subjects whose sitting blood pressure is less than 90/60 mmHg at screening
* Subjects whose pulse is lower than 50 b.p.m. at screening
* Subjects whose PR interval is \>200 msec at screening and prior to dosing
* Subjects whose QTc interval \>450 msec
* Subjects with positive tests for hepatitis B, C, or human immunodeficiency virus (HIV)
Minimum Eligible Age

12 Years

Maximum Eligible Age

16 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ferring Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Development Support

Role: STUDY_DIRECTOR

Ferring Pharmaceuticals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

West Coast Clinical Trials

Cypress, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FE999304 CS01

Identifier Type: -

Identifier Source: org_study_id